RALEIGH, N.C., Feb. 06, 2018 — BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSIâ€™s previously reported BELBUCAÂ® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware.
â€œWe are pleased to have resolved our BELBUCA lawsuit with Teva. We believe that this settlement, together with our previously announced settlement of the lawsuit with Teva regarding BUNAVAILÂ®, provide additional certainty around our patent portfolio and the future potential for our two commercialized products,â€� said Scott Plesha, President of BioDelivery Sciences. â€œImportantly, settling these lawsuits allows us to avoid future litigation costs and thus preserve capital resources.â€�BDSI alleged in the lawsuits that the generic form of BELBUCA which Teva is seeking approval to market in the United States pursuant to three Abbreviated New Drug Application (ANDA) filings with the U.S. Food and Drug Administration (FDA), infringed upon two U.S. patents owned by BDSI. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, BDSI has entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BELBUCA in the U.S. on January 23, 2027 or earlier under certain circumstances. Other terms of the agreement are confidential. About BioDelivery Sciences International, Inc.BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMAÂ®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina. For more information, please visit or follow us:Internet: www.bdsi.com
Twitter: @BioDeliverySIBUNAVAILÂ® (buprenorphine and naloxone) buccal film (CIII) and BELBUCAÂ® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.Cautionary Note on Forward-Looking StatementsThis press release and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI's management and are subject to significant risks and uncertainties, including those detailed in the BDSI's filings with the Securities and Exchange Commission. Actual results (including, without limitation any anticipated benefits of the Companyâ€™s settlement with Teva as described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI's control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.BDSIÂ®, BEMAÂ®, ONSOLISÂ®, BUNAVAILÂ® and BELBUCAÂ® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.Â© 2018 BioDelivery Sciences International, Inc. All rights reserved.Contacts
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
[email protected]Monique Kosse
Latest posts by Editorial Team (see all)
- Dubai Moves to Honour Knowledge Pioneer With $1 Million Mohammed bin Rashid Al Maktoum Knowledge Award - May 20, 2018
- Court Dismisses Andrea Tantaros Lawsuit Against Fox News And Pete Snyder - May 20, 2018
- President Jimmy Carter spurs Liberty University Class of 2018 to success through service - May 19, 2018